Research

Hormonal

GLP-1 receptor agonists (GLP-1RAs) significantly reduce liver fat content and improve histological markers of NASH (resolution without fibrosis worsening) in patients with NAFLD, with efficacy demonstrated across liraglutide, semaglutide, and tirzepatide.

If you have fatty liver disease (NAFLD) or NASH, GLP-1 medications like liraglutide, semaglutide, or tirzepatide are proven to reduce liver fat and improve liver health, often more effectively than placebo. These drugs work through hormonal mechanisms that reduce liver fat independently of weight loss in some cases. While gastrointestinal side effects like nausea are common, they are often manageable. Consult a doctor to see if you are a candidate, especially if you also have Type 2 Diabetes or obesity.

GoodSupportsHIGH confidence
GLP-1RAs are effective in improving the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD.
Han Ah Lee et al. · International Journal of Molecular Sciences · 2023

Why this rating

Multiple phase II RCTs and meta-analyses are cited, though long-term safety/efficacy in cirrhosis remains less clear.

Source

Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease

Han Ah Lee et al. · International Journal of Molecular Sciences · 2023

DOI 10.3390/ijms24119324

narrative_reviewCited 43×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →